Figure 4
Cardiac decompensation by treatment with FK866 in pressure-overloaded mice.
(a) Kaplan-Meier survival curves of mice treated with FK866 (FK) or mock after TAC or sham operation (sham + mock, n = 5; sham + FK, n = 5; TAC + mock, n = 8; TAC + FK, n = 17). (b) NAD+ concentrations in hearts at 7 d after operation (sham + mock, n = 3; sham + FK, n = 3; TAC + mock, n = 8; TAC + FK, n = 5). (c) Sirt1 deacetylase activity in hearts at 7 d after operation (sham + mock, n = 4; sham + FK, n = 4; TAC + mock, n = 7; TAC + FK, n = 5). (d) Immunoblot analysis of Ac-FoxO1 and FoxO1 in hearts at 7 d after operation (sham + mock, n = 3; sham + FK, n = 3; TAC + mock, n = 7; TAC + FK, n = 5). The quantitations of the Ac-FoxO1/FoxO1 are shown as bar graphs. (e) The mRNA levels of mitochondria-associated genes in hearts at 7 d after operation (TAC + mock, n = 12; TAC + FK, n = 6). (f) TUNEL staining (green) with nuclear staining with DAPI (blue) and WGA staining (red) showing the outlines of cardiomyocytes in mice treated with FK866 or mock at 4 d after TAC operation. Scale bars, 40 μm. (g) Quantification of TUNEL-positive cardiomyocytes in hearts at 4 d after operation (TAC + mock, n = 6; TAC + FK, n = 5). *P < 0.05, **P < 0.01, NS, not significant.
